SART3 Antigen and Immunotherapy in Breast Cancer
Author Information
Author(s): Suefuji Y, Sasatomi T, Shichijo S, Nakagawa S, Deguchi H, Koga T, Kameyama T, Itoh K
Primary Institution: Kurume University School of Medicine
Hypothesis
The study investigates the expression of the SART3 antigen in breast cancer to explore its potential for specific immunotherapy.
Conclusion
The SART3 antigen and its derived peptides could be suitable for immunotherapy in most HLA-A24-positive breast cancer patients.
Supporting Evidence
- The SART3 antigen was found in 75% of breast cancer tissue samples tested.
- No SART3 antigen was detected in non-tumorous breast tissue samples.
- SART3-derived peptides induced CTLs that reacted to breast cancer cells.
Takeaway
Researchers found a protein called SART3 in many breast cancer samples, which might help create a treatment that trains the immune system to fight the cancer.
Methodology
The study involved testing breast cancer cell lines and tissue samples for SART3 expression and assessing the induction of CTLs from derived peptides.
Participant Demographics
Breast cancer patients, specifically those who are HLA-A24 positive.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website